Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Follow-Up Questions
IFTBF 주식의 가격 성능은 어떻습니까?
IFTBF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Infant Bacterial Therapeutics AB의 주요 사업 주제나 업종은 무엇입니까?
Infant Bacterial Therapeutics AB은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Infant Bacterial Therapeutics AB의 시가총액은 얼마입니까?
Infant Bacterial Therapeutics AB의 현재 시가총액은 $NaN입니다
